Hip replacement systems recalled
Johnson & Johnson, in conjunction with its DePuy Orthopaedics subsidiary, announced at the end of August 2010 that it is recalling parts used for hip replacements. At issue is the high rate of repeat surgeries needed by people who have received the parts. An estimated 93,000 people will be affected by Johnson & Johnson’s latest product recall.
Affected hip replacement parts involved in the recall include the DePuy ASR XL Acetabular System, and the DePuy ASR Hip Resurfacing System. Physicians were notified about potential problems with the hip replacement parts beginning in March 2011. The decision to recall the parts was made when the results of a new study confirmed a five-year rate of revision surgery of about 12 percent for the ASR resurfacing system and about 13 percent for the ASR XL system, according to DePuy, which is higher than the expected rate.
Subsequent data released in 2011, also from the National Joint Registry for England and Wales (NJR), showed even higher failure rates for DePuy’s ASR hip implants: 17 percent in patients who had their implants for five years and 29 percent for patients who had the devices for six years.
Patients who reported problems in the first five years and had revision surgery reported a variety of symptoms, including pain, swelling and problems walking. These symptoms are normal for patients following a hip replacement, but can be a sign that something is wrong if they continue or come back frequently. These symptoms may indicate serious problems, including:
• Loosening – when the implant does not stay attached to the bone in the correct position
• Fracture – where the bone around the implant may have broken
• Dislocation – where the two parts of the implant that move against each other are no longer aligned.
Please contact your orthopaedic surgeon to determine whether you received a DePuy ASR hip implant. If you don’t know who performed your hip replacement surgery, ask your primary care physician or the hospital where the surgery took place.